Company Announcements

Annual Financial Report 2022 and Notice of AGM

Source: RNS
RNS Number : 5649T
Haleon PLC
20 March 2023

Icon Description automatically generated



Annual Financial Report 2022 and Notice of AGM


20 March 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following documents have been made available to shareholders:


1.       Annual Report and Form 20-F 2022
2.       Notice of 2023 Annual General Meeting (AGM)
3.       Form of Proxy for the 2023 AGM

4.       AGM Voting Instruction Card


A copy of each of the documents has been submitted to the National Storage Mechanism and will shortly be available for inspection at


The Company will also file the Annual Report and Form 20-F 2022 with the US Securities and Exchange Commission today.


The documents referred to above are publicly available on the Company's website at


In compliance with the Disclosure Guidance and Transparency Rules, the Annual Report and Form 20-F 2022, as submitted to the National Storage Mechanism, contains regulated information in unedited full text and is available on the Company's website as noted above.


Shareholders may request a hard copy of the Annual Report and Form 20-F 2022, including the complete audited financial statements of the Company, free of charge from: Company Secretariat, Haleon plc, Building 5, First Floor, The Heights, Weybridge, KT13 0NY, United Kingdom.


Amanda Mellor, Company Secretary


About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.